Identificador persistente para citar o vincular este elemento:
http://hdl.handle.net/10553/47719
Campo DC | Valor | idioma |
---|---|---|
dc.contributor.author | Clavo, Bernardino | en_US |
dc.contributor.author | Ceballos Santos, Daniel Sebastián | en_US |
dc.contributor.author | Gutierrez, Dominga | en_US |
dc.contributor.author | Rovira, Gloria | en_US |
dc.contributor.author | Suarez, Gerardo | en_US |
dc.contributor.author | López Ríos,Laura | en_US |
dc.contributor.author | Pinar Sedeño, María Beatriz | en_US |
dc.contributor.author | Cabezón Pons, María Auxiliadora | en_US |
dc.contributor.author | Morales, Victoria | en_US |
dc.contributor.author | Oliva, Elena | en_US |
dc.contributor.author | Fiuza Pérez, Mª Dolores | en_US |
dc.contributor.author | Santana Rodríguez, Norberto | en_US |
dc.date.accessioned | 2018-11-23T15:51:04Z | - |
dc.date.available | 2018-11-23T15:51:04Z | - |
dc.date.issued | 2013 | en_US |
dc.identifier.issn | 0885-3924 | en_US |
dc.identifier.uri | http://hdl.handle.net/10553/47719 | - |
dc.description.abstract | Context Persistent or severe hemorrhagic radiation proctitis (HRP) has limited therapeutic options. Objectives To describe our experience with ozone therapy (O3T) in the management of refractory HRP. Methods Patients (n = 17; median age 69 years [range 42–80 years]) previously irradiated for prostate or uterine cancer and suffering persistent or severe HRP without response to conventional treatment were enrolled to receive an O3/O2 gas mixture via rectal insufflations and topical application of ozonized oil. Most of the patients (83%) had Grade 3 or Grade 4 toxicity. Median follow-up post-O3T was 40 months (range 3–56 months). Results Endoscopic treatments required were: 43 (median 1; range 0–10) pre-O3T; 17 (median 0; range 0–8; P = 0.063) during O3T; and five (median 0; range 0–2; P = 0.008) during follow-up. Hemoglobin levels were 10.35 g/dL (7–14 g/dL) pre-O3T and 13 g/dL (9–15 g/dL) (P = 0.001) post-O3T. Median toxicity grades were 3 (range 2–4) pre-O3T, 1 (range 0–2; P < 0.001) at the end of O3T, and 0 (range 0–1; P < 0.001) at the last follow-up. Conclusion Persistent advanced HRP was significantly improved with O3T. The addition of O3T can be useful as a complementary treatment in the long-term management of HRP and, as such, merits further evaluation. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Journal of Pain and Symptom Management | en_US |
dc.source | Journal of Pain and Symptom Management[ISSN 0885-3924],v. 46, p. 106-112 | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject | 3201 Ciencias clínicas | en_US |
dc.subject.other | Gynecologic tumors | en_US |
dc.subject.other | Integrative and complementary medicine | en_US |
dc.subject.other | Pelvic radiotherapy | en_US |
dc.subject.other | Prostate cancer | en_US |
dc.subject.other | Rectal bleeding | en_US |
dc.subject.other | Side effects | en_US |
dc.subject.other | Toxicity | en_US |
dc.title | Long-term control of refractory hemorrhagic radiation proctitis with ozone therapy | en_US |
dc.type | info:eu-repo/semantics/article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1016/j.jpainsymman.2012.06.017 | en_US |
dc.identifier.scopus | 2-s2.0-84880300836 | - |
dc.contributor.authorscopusid | 57190093030 | - |
dc.contributor.authorscopusid | 15834224200 | - |
dc.contributor.authorscopusid | 8616778800 | - |
dc.contributor.authorscopusid | 6506763433 | - |
dc.contributor.authorscopusid | 7101855600 | - |
dc.contributor.authorscopusid | 56243678000 | - |
dc.contributor.authorscopusid | 6507421079 | - |
dc.contributor.authorscopusid | 14119160800 | - |
dc.contributor.authorscopusid | 55425541700 | - |
dc.contributor.authorscopusid | 57196105246 | - |
dc.contributor.authorscopusid | 6506332517 | - |
dc.contributor.authorscopusid | 56072780900 | - |
dc.description.lastpage | 112 | en_US |
dc.description.firstpage | 106 | en_US |
dc.relation.volume | 46 | en_US |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.description.numberofpages | 7 | en_US |
dc.utils.revision | Sí | en_US |
dc.date.coverdate | Julio 2013 | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.sjr | 1,712 | - |
dc.description.jcr | 2,737 | - |
dc.description.sjrq | Q1 | - |
dc.description.jcrq | Q1 | - |
dc.description.scie | SCIE | - |
item.grantfulltext | none | - |
item.fulltext | Sin texto completo | - |
crisitem.author.dept | GIR IUIBS: Farmacología Molecular y Traslacional | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.dept | Departamento de Ciencias Clínicas | - |
crisitem.author.dept | GIR IUIBS: Farmacología Molecular y Traslacional | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | GIR IUIBS: Farmacología Molecular y Traslacional | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.orcid | 0000-0003-2522-1064 | - |
crisitem.author.orcid | 0000-0003-2384-4524 | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.fullName | Clavo Varas,Bernardino | - |
crisitem.author.fullName | Ceballos Santos, Daniel Sebastián | - |
crisitem.author.fullName | López Ríos,Laura | - |
crisitem.author.fullName | Pinar Sedeño, María Beatriz | - |
crisitem.author.fullName | Cabezón Pons, María Auxiliadora | - |
crisitem.author.fullName | Fiuza Pérez,Mª Dolores | - |
crisitem.author.fullName | Santana Rodríguez,Norberto | - |
Colección: | Artículos |
Citas SCOPUSTM
23
actualizado el 17-nov-2024
Citas de WEB OF SCIENCETM
Citations
21
actualizado el 17-nov-2024
Visitas
54
actualizado el 20-jul-2024
Google ScholarTM
Verifica
Altmetric
Comparte
Exporta metadatos
Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.